Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Deferred Taxes: 2014-2020

Historic Deferred Taxes for Enanta Pharmaceuticals (ENTA) over the last 6 years, with Sep 2020 value amounting to $15.0 million.

  • Enanta Pharmaceuticals' Deferred Taxes rose 1363.63% to $15.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was $10.6 million, marking a year-over-year increase of 438.05%. This contributed to the annual value of $345,000 for FY2021, which is 96.75% down from last year.
  • According to the latest figures from Q3 2020, Enanta Pharmaceuticals' Deferred Taxes is $15.0 million, which was up 576.58% from -$3.1 million recorded in Q2 2020.
  • In the past 5 years, Enanta Pharmaceuticals' Deferred Taxes ranged from a high of $15.0 million in Q3 2020 and a low of -$3.8 million during Q2 2017.
  • Moreover, its 3-year median value for Deferred Taxes was -$495,000 (2018), whereas its average is $606,000.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Deferred Taxes crashed by 5,816.67% in 2016, and later soared by 1,363.63% in 2020.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Deferred Taxes stood at -$1.9 million in 2016, then skyrocketed by 239.37% to $2.7 million in 2017, then plummeted by 134.49% to -$918,000 in 2018, then soared by 171.57% to $657,000 in 2019, then spiked by 1,363.63% to $15.0 million in 2020.
  • Its Deferred Taxes was $15.0 million in Q3 2020, compared to -$3.1 million in Q2 2020 and -$1.9 million in Q1 2020.